Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

262,526 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of potent and selective TACE inhibitors via the S1 pocket.
Condon JS, Joseph-McCarthy D, Levin JI, Lombart HG, Lovering FE, Sun L, Wang W, Xu W, Zhang Y. Condon JS, et al. Among authors: zhang y. Bioorg Med Chem Lett. 2007 Jan 1;17(1):34-9. doi: 10.1016/j.bmcl.2006.10.004. Epub 2006 Oct 5. Bioorg Med Chem Lett. 2007. PMID: 17064892
Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.
Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS. Levin JI, et al. Among authors: zhang y. Bioorg Med Chem Lett. 2003 Aug 18;13(16):2799-803. doi: 10.1016/s0960-894x(03)00514-6. Bioorg Med Chem Lett. 2003. PMID: 12873518
Therapeutic potential of TACE inhibitors in stroke.
Lovering F, Zhang Y. Lovering F, et al. Among authors: zhang y. Curr Drug Targets CNS Neurol Disord. 2005 Apr;4(2):161-8. doi: 10.2174/1568007053544147. Curr Drug Targets CNS Neurol Disord. 2005. PMID: 15857301 Review.
Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme.
Zhang Y, Hegen M, Xu J, Keith JC Jr, Jin G, Du X, Cummons T, Sheppard BJ, Sun L, Zhu Y, Rao VR, Wang Q, Xu W, Cowling R, Nickerson-Nutter CL, Gibbons J, Skotnicki J, Lin LL, Levin J. Zhang Y, et al. Int Immunopharmacol. 2004 Dec 20;4(14):1845-57. doi: 10.1016/j.intimp.2004.08.003. Int Immunopharmacol. 2004. PMID: 15531300
Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.
Zhang Y, Xu J, Levin J, Hegen M, Li G, Robertshaw H, Brennan F, Cummons T, Clarke D, Vansell N, Nickerson-Nutter C, Barone D, Mohler K, Black R, Skotnicki J, Gibbons J, Feldmann M, Frost P, Larsen G, Lin LL. Zhang Y, et al. J Pharmacol Exp Ther. 2004 Apr;309(1):348-55. doi: 10.1124/jpet.103.059675. Epub 2004 Jan 12. J Pharmacol Exp Ther. 2004. PMID: 14718605
262,526 results
You have reached the last available page of results. Please see the User Guide for more information.